English
This article is from The Indian Journal of Medical Research , volume 138 . Abstract Background & objectives:: Biapenem is a newly developed carbapenem to treat moderate and severe bacterial infections. This multicenter, randomized, parallel-controlled clinical trial was conducted to compare the clinical efficacy, bacterial eradication rates and safety of biapenem and meropenem in the treatment of bacterial lower respiratory tract infections and urinary tract infections (UTIs) at nine centres in China. Methods:: Patients diagnosed with bacterial lower respiratory tract infections or UTIs were randomly assigned to receive either biapenem (300 mg every 12 h) or meropenem (500 mg every 8 h) by intravenous infusion for 7 to 14 days according to their disease severity. The overall clinical efficacy, bacterial eradication rates and drug-related adverse reactions of biapenem and meropenem were analyzed. Results:: A total of 272 enrolled cases were included in the intent-to-treat (ITT) analysis and safety analysis. There were no differences in demographics and baseline medical characteristics between biapenem group and meropenem group. The overall clinical efficacies of biapenem and meropen
Sign in with your free account to read, download EPUBs or listen.
Ebook · Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial. · Wang, Xiaohui, Zhang, Xiaoke, Zong, Zhiyong, Yu, Rujia, Lv, Xiaoju, Xin, Jianbao, Tong, Chaohui, Hao, Qinglin · Internet Archive